Prasugrel, a third generation thienopyridine and potent platelet inhibitor

P. A. Gurbel, U. S. Tantry

Research output: Contribution to journalArticle

Abstract

Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.

Original languageEnglish (US)
Pages (from-to)324-336
Number of pages13
JournalCurrent Opinion in Investigational Drugs
Volume9
Issue number3
StatePublished - Mar 2008

Fingerprint

Platelet Aggregation Inhibitors
Thienopyridines
Phase III Clinical Trials
Thromboembolism
Acute Coronary Syndrome
Japan
Stroke
Pharmaceutical Preparations
Prasugrel Hydrochloride
thienopyridine
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Prasugrel, a third generation thienopyridine and potent platelet inhibitor. / Gurbel, P. A.; Tantry, U. S.

In: Current Opinion in Investigational Drugs, Vol. 9, No. 3, 03.2008, p. 324-336.

Research output: Contribution to journalArticle

@article{93cd574e656641a3af119849610a84ec,
title = "Prasugrel, a third generation thienopyridine and potent platelet inhibitor",
abstract = "Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.",
author = "Gurbel, {P. A.} and Tantry, {U. S.}",
year = "2008",
month = "3",
language = "English (US)",
volume = "9",
pages = "324--336",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Prasugrel, a third generation thienopyridine and potent platelet inhibitor

AU - Gurbel, P. A.

AU - Tantry, U. S.

PY - 2008/3

Y1 - 2008/3

N2 - Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.

AB - Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.

UR - http://www.scopus.com/inward/record.url?scp=40049105525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40049105525&partnerID=8YFLogxK

M3 - Article

C2 - 18311669

AN - SCOPUS:40049105525

VL - 9

SP - 324

EP - 336

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 3

ER -